{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Deprescribing at the End of Life: Jennifer Tjia, Jon Furuno, Simon Mooijaart","description":"Philippe Pinel  remarked in 1800 that \u201cIt is an art of no little importance to administer medicines properly, but it is an art of much greater and more difficult acquisition to know when to suspend or altogether to omit them.\u201d This insight remains profoundly relevant today, especially in hospice care, where inappropriate prescribing is a common issue. Studies show that 20%\u201370% of hospice patients receive at least one unnecessary medication near the end of life, including drugs like antihypertensives, statins, and vitamins. In this episode of the GeriPal Podcast, we tackle the pressing topic of deprescribing at the end of life with expert guests Jennifer Tjia,  Jon Furuno, and Simon Mooijaart. The conversation focuses on identifying medications that should almost always be discontinued\u2014such as statins, osteoporosis meds, finasteride, and vitamins, which offer minimal benefit for patients with limited life expectancy. We also delve into more nuanced cases, such as antithrombotics, which present complex decisions that challenge clinicians, particularly when prognosis spans the many weeks to months range. Finally, we explore practical strategies for engaging patients and families in deprescribing conversations. Our guests highlight tools such as the  FRAME mnemonic (Focus on the goals of care, Review current medications, Assess each medication\u2019s risk\/benefit, Minimize the medication burden, and Evaluate regularly) and the  Goal Concurrent Prescribing tool, which helps ensure medication decisions align with patients\u2019 values and end-of-life priorities. By: Eric Widera  Other resources discussed in the podcast    Prevalence and Factors Associated With Receiving a Prescription for Antithrombotic Therapy on Hospice Admission,\u201d JAGS. 2025    Discontinuation of Anticoagulants and Occurrence of Bleeding and Thromboembolic Events in Vitamin K Antagonist Users with a Life-limiting Disease. 2025   Effects of the discontinuation of antihypertensive treatment on neuropsychiatric symptoms and quality of life in nursing home residents with dementia (DANTON): a multicentre, open-label, blinded-outcome, randomised controlled trial. 2024   Perspectives on deprescribing in palliative care. Expert Review of Clinical Pharmacology. 2023    Developing a decision support tool for the continuation or deprescribing of antithrombotic therapy in patients receiving end-of-life care: Results of a European Delphi study. Thrombosis Research. 2025   Human-Centered Design Development and Acceptability Testing of a Goal Concordant Prescribing Program in Hospice. JPM 2025   Reduction of Antihypertensive Treatment in Nursing Home Residents. NEJM 2025   &amp;nbsp; ","author_name":"GeriPal - A Geriatrics and Palliative Medicine Podcast","author_url":"http:\/\/www.geripal.org","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/40234210\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/40234210"}